{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-063653","form_type":"8-K","ticker":null,"cik":"0001012477","company_name":"AVADEL PHARMACEUTICALS PLC","filed_at":"2024-05-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.872572+00:00","generated_at":"2026-06-01T10:15:53.426488+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Avadel Pharmaceuticals appoints Naseem Amin, M.D. to Board of Directors","bullets":["Naseem Amin appointed effective May 17, 2024, as independent director.","Granted option to purchase 49,500 shares at $15.94, vesting over three years.","Amin is CEO of Orphalan SA with 30 years experience in biopharma and venture capital.","Board cites Amin's expertise to support commercial launch of LUMRYZ for narcolepsy."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-063653","json":"https://secwatch.observer/filing/0001104659-24-063653.json","markdown":"https://secwatch.observer/filing/0001104659-24-063653.md","text":"https://secwatch.observer/filing/0001104659-24-063653.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1012477/000110465924063653/0001104659-24-063653-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1012477/000110465924063653/tm2414924d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T10:15:53.426488+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09607745c4","claim":"Naseem Amin, MD was appointed as Director at AVADEL PHARMACEUTICALS PLC.","evidence_excerpt":"On May 17, 2024, the Board of Directors (the “Board”) of Avadel Pharmaceuticals plc (the “Company”) appointed Naseem Amin, MD to the Board, effective as of May 17, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465924063653/0001104659-24-063653-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}